GLP1R and type 2 diabetes mellitus: The GRADE trial assessed four mediations currently in use with metformin for the maintenance of type 2 diabetes, including insulin glargine, a long-acting insulin analog; liraglutide, a GLP-1 agonist; glimepiride, a sulfonylurea; and sitagliptin, a DPP-4 antagonist.